Loading company…
Menlo Park diagnostics company offering the MSDA blood test to support multiple sclerosis treatment decisions.
Founded in 2014 in Menlo Park, US, Octave Bioscience Inc develops diagnostic solutions for neurodegenerative diseases, led by CEO Doug Biehn. Its MSDA Test is a simple blood test that gives clinically relevant insight into multiple sclerosis disease activity, helping clinicians decide on disease-modifying therapies and further testing. Clinicians order the test and Octave charges a set fee per test. In November 2023 the company received USD 10.00 mn in grant funding from the Michael J. Fox Foundation. In September 2025 it raised USD 35 million in Series C funding from Valhalla Foundation and Byers Capital, and USD 15.5 million in venture debt from Silicon Valley Bank.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in